Clinical trials authorised by Health Canada — search by condition or drug, landscape counts and sponsor detail for your AI agent.
For pharma BD, CROs, investors, patient-advocacy and med-affairs teams. Free: keyword search. Pro: full results, live sponsor/drug detail and condition landscapes.
trial_search, no sign-up. Pro: C$15/month — all tools, unlimited use. Cancel anytime (one click on the success page, or email).trial_search (free) — FREE. Health Canada-authorised clinical trials for a condition or drug keyword — newest 5.trial_search_full (Pro) — PRO. Up to 200 trials for a keyword, optionally started since a date.trial_detail (Pro) — PRO. Live detail for a protocol id: sponsor/manufacturer, drug products and study population.condition_landscape (Pro) — PRO. Trial counts per year and most common co-listed conditions for a keyword — competitive landscape.trial_search {"keyword":"diabetes"}
{
"keyword": "diabetes",
"found": 297,
"latest_5": [
{
"protocol_id": 28257,
"protocol_no": "CLIK066A2202",
"title": "A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP DOSE-FINDING STUDY TO EVALUATE THE CHANGE IN HBA1C AFTER 12 WEEKS MONOTHERAPY WITH LIK066 DOSES RANGING FROM 2.5 MG TO 150 MG DAILY TAKEN Q.D., B.I.D",
"conditions": [
"TYPE 2 DIABETES"
],
"start": null,
"end": null,
"status_id": 3
},
{
"protocol_id": 47760,
"protocol_no": "ERADICATE-HF",
"title": "ERTUGLIFLOZIN TRIAL IN DIABETES WITH PRESERVED OR REDUCED EJECTION FRACTION MECHANISTIC EVALUATION IN HEART FAILURE: \"ERADICATE-HF\"",
"conditions": [
"HEART FAILURE",
"HEART FAILURE WITH PRESERVED EJECTION FRACTION",
"DIABETES"
],
"start": null,
"end": null,
"status_id": 3
},
{
"protocol_id": 63333,
"protocol_no": "U1111-1268-1934",
"title": "THE GLP-1 AGONIST SEMAGLUTIDE FOR THE TREATMENT OF METABOLIC DISEASE IN LIVER TRANSPLANT RECIPIENTS: A PHASE IV, RANDOMIZED TRIAL",
"conditions": [
"LIVER TRANSPLANTATION",
"TYPE 2 DIABETES"
],
"start": null,
"end": null,
"status_id": 3
},
{
"protocol_id": 69438,
"protocol_no": "REMODELT1D2023",
"title": "RANDOMIZED TRIAL OF SEMAGLUTIDE FOR DIABETIC KIDNEY DISEASE IN TYPE 1 DIABETES",
"conditions": [
"TYPE 1 DIABETES"
],
"start": null,
"end": null,
"status_id": 3
},
{
"protocol_id": 47665,
"protocol_no": "I8H-MC-BDCB",
"title": "SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3209590 FOLLOWING MULTIPLE WEEKLY DOSES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS",
"conditions": [
"TYPE 2 DIABETES"
],
"start": null,
"end": null,
"status_id": 3
}
],
"pro": "Full results (200), date filters, sponsor/drug detail via live API, condition landscapes: https://ca-clinical-trials-mcp.donniertf.workers.dev/buy",
"disclaimer": "Snapshot of Health Canada's Clinical Trials Database (as of 2026-10-14, 9736 protocols authorised for drugs in Canada). Not medical advice; check the official database and sponsor for enrolment."
}
Add https://ca-clinical-trials-mcp.donniertf.workers.dev/mcp to Claude, Cursor or any MCP client (Streamable HTTP, no login for the free tier). Subscribers pass access_token or Authorization: Bearer.
Snapshot of Health Canada's Clinical Trials Database (as of 2026-10-14, 9736 protocols authorised for drugs in Canada). Not medical advice; check the official database and sponsor for enrolment.
llms.txt · server card · pricing.json · POST /checkout → checkout URL · GET /token?session_id= → access token.
Save with Canada bundles: ca-mcp-bundles · GitHub hub.
Questions, refunds or cancelling: dmorrisonwebdesign@gmail.com. Run by Donnie Morrison, UK. Payments by Stripe; we never see card details.